



## Clinical trial results: Pilot study with Staatl. Fachingen STILL for functional dyspepsia (particularly heartburn)

### Summary

EudraCT number	2013-001256-36
Trial protocol	DE
Global end of trial date	04 June 2014

### Results information

Result version number	v1 (current)
This version publication date	25 April 2022
First version publication date	25 April 2022

### Trial information

#### Trial identification

Sponsor protocol code	FACH/023212
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Fachingen Heil- und Mineralbrunnen GmbH
Sponsor organisation address	Brunnenstrasse 11, Birlenbach OT Fachingen/Lahn, Germany, 65626
Public contact	Marketing Staatl. Fachingen, Fachingen Heil- und Mineralbrunnen GmbH, 0049 6432983468, heiner.wolters@fachingen.de
Scientific contact	Marketing Staatl. Fachingen, Fachingen Heil- und Mineralbrunnen GmbH, 0049 6432983468, heiner.wolters@fachingen.de

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 July 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	04 June 2014
Was the trial ended prematurely?	No

Notes:

---

## General information about the trial

Main objective of the trial:

Investigation of the efficacy and tolerability of Staatl. Fachingen STILL in the pre / post comparison.

Efficacy parameters:

- Therapeutic course based on the questionnaire data (questionnaires "Reflux Disease Questionnaire" (RDQ) / "Quality of Life in Reflux and Dyspepsia" (QOLRAD) / "Gastrointestinal Quality of Life Index" (GLQI))
- Difference in the frequency of heartburn episodes per week
- Difference in the subjective perception of well-being (SF-12 questionnaire )
- Differences in laboratory parameters (liver function, lipid metabolism)
- Difference in body weight
- Global assessment of efficacy by patient and investigator

Tolerability parameters:

- Adverse events (AEs)
- Difference in blood pressure
- Global assessment of tolerability by patient and investigator

---

Protection of trial subjects:

Prior to recruitment of patients, all relevant documents of the clinical study were submitted and proved by the Independent Ethics Committees (IECs) responsible for the participating investigators. Written consent documents embodied the elements of informed consent as described in the Declaration of Helsinki, the ICH Guidelines for Good Clinical Practice (GCP) and were in accordance with all applicable laws and regulations. The informed consent form and patient information sheet described the planned and permitted uses, transfers and disclosures of the patient's personal data and personal health information for purposes of conducting the study. The informed consent form and the patient information sheet further explained the nature of the study, its objectives and potential risks and benefits as well as the date informed consent was given. Before being enrolled in the clinical trial, every patient was informed that participation in this trial was voluntary and that he/she could withdraw from the study at any time without giving a reason and without having to fear any loss in his/her medical care. The patient's consent was obtained in writing before the start of the study. By signing the informed consent, the patient declared that he/she was participating voluntarily and intended to follow the study protocol instructions and the instructions of the investigator and to answer the questions asked during the course of the trial.

---

Background therapy:

Patients were instructed to use medication for treatment of heartburn only in case of an emergency as a rescue medication. Intake of rescue medication was documented by the patients in a diary.

---

Evidence for comparator:

No comparator was used for this pilot study.

Actual start date of recruitment	10 July 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 56
Worldwide total number of subjects	56
EEA total number of subjects	56

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	56
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Data sets are available for 56 patients.

### Pre-assignment

Screening details:

25 screening failures were documented.

### Period 1

Period 1 title	Treatment (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Treatment
-----------	-----------

Arm description:

This treatment arm has been created due to technical reason, as no single arm trial can be entered into the system. All data given for this fictive treatment arm are similar to the data given for the full analysis set

Arm type	Experimental
Investigational medicinal product name	Heilwasser Staatl. Fachingen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

Daily intake of 1,5 liters throughout the day. 200-500 ml of IMP should be drunk 15 - 30 minutes before each main meal or with the meal, if needed.

Number of subjects in period 1	Treatment
Started	56
Completed	56

## Baseline characteristics

### Reporting groups

Reporting group title	Treatment
Reporting group description: This treatment arm has been created due to technical reason, as no single arm trial can be entered into the system. All data given for this fictive treatment arm are similar to the data given for the full analysis set	

Reporting group values	Treatment	Total	
Number of subjects	56	56	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	56	56	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	37.0		
standard deviation	± 12.0	-	
Gender categorical Units: Subjects			
Female	30	30	
Male	26	26	

### Subject analysis sets

Subject analysis set title	Safety population
Subject analysis set type	Safety analysis
Subject analysis set description: The safety analysis set includes all patients, who have taken the IMP at least once and from whom safety parameters are available.	
Subject analysis set title	FAS population
Subject analysis set type	Full analysis
Subject analysis set description: The full analysis set includes all patients who haven taken the IMP at least once and from whom efficacy data were available.	
Subject analysis set title	VCAS population
Subject analysis set type	Per protocol
Subject analysis set description: The VCAS analysis set includes all patients who used the IMP according to the clinical trial protocol and from whom no serious deviation from the protocol were documented.	

Reporting group values	Safety population	FAS population	VCAS population
Number of subjects	56	53	40
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	56	53	40
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	37.0	36.2	35.7
standard deviation	± 12.0	± 11.7	± 11.9
Gender categorical Units: Subjects			
Female	30	28	22
Male	26	25	18

## End points

### End points reporting groups

Reporting group title	Treatment
-----------------------	-----------

Reporting group description:

This treatment arm has been created due to technical reason, as no single arm trial can be entered into the system. All data given for this fictive treatment arm are similar to the data given for the full analysis set

Subject analysis set title	Safety population
----------------------------	-------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

The safety analysis set includes all patients, who have taken the IMP at least once and from whom safety parameters are available.

Subject analysis set title	FAS population
----------------------------	----------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

The full analysis set includes all patients who haven taken the IMP at least once and from whom efficacy data were available.

Subject analysis set title	VCAS population
----------------------------	-----------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

The VCAS analysis set includes all patients who used the IMP according to the clinical trial protocol and from whom no serious deviation from the protocol were documented.

### Primary: Frequency of heartburn episodes

End point title	Frequency of heartburn episodes
-----------------	---------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: number per week				
arithmetic mean (standard deviation)				
V2	7.09 (± 7.49)	7.09 (± 7.49)		
V3	3.02 (± 2.64)	3.02 (± 2.64)		
V4	2.32 (± 3.44)	2.32 (± 3.44)		

### Statistical analyses

Statistical analysis title	Change of frequency of heartburn (V2 vs. V3)
----------------------------	--

Comparison groups	Treatment v FAS population
-------------------	----------------------------

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-4.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.01
upper limit	-2.14
Variability estimate	Standard deviation
Dispersion value	7.01

Notes:

[1] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system

<b>Statistical analysis title</b>	Change of frequency of heartburn (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[2]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-4.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.05
upper limit	-2.5
Variability estimate	Standard deviation
Dispersion value	8.24

Notes:

[2] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system

### Primary: Duration of heartburn per week

End point title	Duration of heartburn per week
End point description:	
End point type	Primary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	



End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: minute				
arithmetic mean (standard deviation)				
V2	35.2 (± 41.4)	35.2 (± 41.4)		
V3	16.3 (± 17.4)	16.3 (± 17.4)		
V4	9.4 (± 11.6)	9.4 (± 11.6)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of duration of heartburn (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[3]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-18.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.9
upper limit	-9.7
Variability estimate	Standard deviation
Dispersion value	32.8

Notes:

[3] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change of duration of heartburn (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[4]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-25.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.8
upper limit	-15.6
Variability estimate	Standard deviation
Dispersion value	36.4

Notes:

[4] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: RDQ dimension heartburn

End point title	RDQ dimension heartburn
-----------------	-------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: Score				
arithmetic mean (standard deviation)				
V2	6.36 (± 4.56)	6.36 (± 4.56)		
V3	4.23 (± 3.85)	4.23 (± 3.85)		
V4	1.92 (± 2.40)	1.92 (± 2.40)		

## Statistical analyses

Statistical analysis title	Change RDQ dimension heartburn (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[5]</sup>
P-value	= 0.002
Method	Wilcoxon (Mann-Whitney)
Parameter estimate	Mean difference (final values)
Point estimate	-2.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.44
upper limit	-0.82
Variability estimate	Standard deviation
Dispersion value	4.74

Notes:

[5] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Change RDQ dimension heartburn (V2 vs. V4)
----------------------------	--

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[6]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-4.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.57
upper limit	-3.3
Variability estimate	Standard deviation
Dispersion value	4.11

Notes:

[6] - explorative

## Secondary: RDQ dimension regurgitation

End point title	RDQ dimension regurgitation
-----------------	-----------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	52	52		
Units: Score				
arithmetic mean (standard deviation)				
V2	7.46 (± 4.25)	7.46 (± 4.25)		
V3	4.08 (± 3.58)	4.08 (± 3.58)		
V4	2.60 (± 2.96)	2.60 (± 2.96)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of RDQ dimension regurgitation (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other <sup>[7]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-3.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.59
upper limit	-2.18
Variability estimate	Standard deviation
Dispersion value	4.32

Notes:

[7] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change of RDQ dimension regurgitation (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other <sup>[8]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-4.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.04
upper limit	3.69
Variability estimate	Standard deviation
Dispersion value	4.21

Notes:

[8] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: RDQ dimension GERD

End point title	RDQ dimension GERD
End point description:	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	52	52		
Units: Score				
arithmetic mean (standard deviation)				
V2	13.79 (± 6.32)	13.79 (± 6.32)		
V3	8.23 (± 5.36)	8.23 (± 5.36)		
V4	4.56 (± 3.93)	4.56 (± 3.93)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of RDQ dimension GERD (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other <sup>[9]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-5.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.34
upper limit	-3.77
Variability estimate	Standard deviation
Dispersion value	6.4

Notes:

[9] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change of RDQ dimension GERD (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other <sup>[10]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-9.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.1
upper limit	-7.36
Variability estimate	Standard deviation
Dispersion value	6.69

Notes:

[10] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: RDQ dimension dyspepsia

End point title	RDQ dimension dyspepsia
-----------------	-------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	51	51		
Units: Score				
arithmetic mean (standard deviation)				
V2	6.24 (± 4.16)	6.24 (± 4.16)		
V3	3.86 (± 3.30)	3.86 (± 3.30)		
V4	2.47 (± 3.05)	2.47 (± 3.05)		

## Statistical analyses

Statistical analysis title	Change of RDQ dimension dyspepsia (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	102
Analysis specification	Pre-specified
Analysis type	other <sup>[11]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-2.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.49
upper limit	-1.25
Variability estimate	Standard deviation
Dispersion value	3.97

Notes:

[11] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Change of RDQ dimension dyspepsia (V2 vs. V4)
----------------------------	---

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	102
Analysis specification	Pre-specified
Analysis type	other <sup>[12]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-3.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.99
upper limit	-2.54
Variability estimate	Standard deviation
Dispersion value	4.35

Notes:

[12] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: GLQI totals score

End point title	GLQI totals score
End point description:	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: Score				
arithmetic mean (standard deviation)				
V2	108.3 (± 16.0)	108.3 (± 16.0)		
V3	115.8 (± 13.9)	115.8 (± 13.9)		
V4	121.5 (± 14.0)	121.5 (± 14.0)		

### Statistical analyses

Statistical analysis title	Change of GLQI total score (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[13]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	7.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.18
upper limit	10.8
Variability estimate	Standard deviation
Dispersion value	12

Notes:

[13] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change of GLQI total score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[14]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	13.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.7
upper limit	16.6
Variability estimate	Standard deviation
Dispersion value	12.51

Notes:

[14] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: GLQI dimension symptoms

End point title	GLQI dimension symptoms
End point description:	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	



End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: Score				
arithmetic mean (standard deviation)				
V2	56.2 (± 9.0)	56.2 (± 9.0)		
V3	60.9 (± 8.0)	60.9 (± 8.0)		
V4	65.0 (± 7.9)	65.0 (± 7.9)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of GLQI dimension symptoms (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[15]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	4.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.53
upper limit	6.98
Variability estimate	Standard deviation
Dispersion value	8.06

Notes:

[15] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change of GLQI dimension symptoms (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[16]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	8.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.74
upper limit	10.96
Variability estimate	Standard deviation
Dispersion value	7.64

Notes:

[16] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: GLQI dimension emotions

End point title	GLQI dimension emotions
-----------------	-------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	13.2 (± 2.7)	13.2 (± 2.7)		
V3	14.2 (± 2.2)	14.2 (± 2.2)		
V4	14.4 (± 2.0)	14.4 (± 2.0)		

## Statistical analyses

Statistical analysis title	Change of GLQI dimension emotions (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[17]</sup>
P-value	= 0.002
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.35
upper limit	1.5
Variability estimate	Standard deviation
Dispersion value	2.06

Notes:

[17] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Change of GLQI dimension emotions (V2 vs. V4)
----------------------------	---

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[18]</sup>
P-value	= 0.002
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	1.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.42
upper limit	1.85
Variability estimate	Standard deviation
Dispersion value	2.57

Notes:

[18] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: GLQI dimension physical function

End point title	GLQI dimension physical function
End point description:	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: Score				
arithmetic mean (standard deviation)				
V2	20.8 (± 3.9)	20.8 (± 3.9)		
V3	22.5 (± 3.7)	22.5 (± 3.7)		
V4	23.3 (± 3.8)	23.3 (± 3.8)		

### Statistical analyses

Statistical analysis title	Change of GLQI "physical function" (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[19]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	1.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	2.63
Variability estimate	Standard deviation
Dispersion value	3.22

Notes:

[19] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change of GLQI "physical function" (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[20]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	2.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.55
upper limit	3.55
Variability estimate	Standard deviation
Dispersion value	3.6

Notes:

[20] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: GLQI dimension social function

End point title	GLQI dimension social function
End point description:	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: Score				
arithmetic mean (standard deviation)				
V2	14.4 (± 2.3)	14.4 (± 2.3)		
V3	14.5 (± 2.3)	14.5 (± 2.3)		
V4	15.0 (± 1.8)	15.0 (± 1.8)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of GLQI "social function" (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[21]</sup>
P-value	= 0.519
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.32
upper limit	0.62
Variability estimate	Standard deviation
Dispersion value	1.69

Notes:

[21] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change of GLQI "social function" (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[22]</sup>
P-value	= 0.017
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.12
upper limit	1.2
Variability estimate	Standard deviation
Dispersion value	1.94

Notes:

[22] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: QOLRAD domain "emotional distress"

End point title	QOLRAD domain "emotional distress"
-----------------	------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	5.74 (± 1.17)	5.74 (± 1.17)		
V3	6.36 (± 0.77)	6.36 (± 0.77)		
V4	6.57 (± 0.72)	6.57 (± 0.72)		

## Statistical analyses

Statistical analysis title	Changes in QOLRAD domain score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[23]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.31
upper limit	0.94
Variability estimate	Standard deviation
Dispersion value	1.12

Notes:

[23] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Changes in QOLRAD domain score (V2 vs. V4)
----------------------------	--

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[24]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	1.13
Variability estimate	Standard deviation
Dispersion value	1.06

Notes:

[24] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: QOLRAD domain "sleep disturbance"

End point title	QOLRAD domain "sleep disturbance"
End point description:	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	5.75 (± 1.12)	5.75 (± 1.12)		
V3	6.27 (± 0.78)	6.27 (± 0.78)		
V4	6.57 (± 0.70)	6.57 (± 0.70)		

### Statistical analyses

Statistical analysis title	Changes in QOLRAD domain score (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[25]</sup>
P-value	= 0.003
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.17
upper limit	0.86
Variability estimate	Standard deviation
Dispersion value	1.23

Notes:

[25] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Changes in QOLRAD domain score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[26]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.52
upper limit	1.11
Variability estimate	Standard deviation
Dispersion value	1.05

Notes:

[26] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### **Secondary: QOLRAD domain "food/drink problems"**

End point title	QOLRAD domain "food/drink problems"
End point description:	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	



End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	5.22 (± 1.17)	5.22 (± 1.17)		
V3	6.07 (± 0.75)	6.07 (± 0.75)		
V4	6.38 (± 0.72)	6.38 (± 0.72)		

## Statistical analyses

<b>Statistical analysis title</b>	Changes in QOLRAD domain score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[27]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.12
Variability estimate	Standard deviation
Dispersion value	1

Notes:

[27] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Changes in QOLRAD domain score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[28]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	1.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.87
upper limit	1.44
Variability estimate	Standard deviation
Dispersion value	1.02

Notes:

[28] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: QOLRAD domain "physical/social functioning

End point title	QOLRAD domain "physical/social functioning
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 4 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	6.20 (± 0.80)	6.20 (± 0.80)		
V3	6.56 (± 0.61)	6.56 (± 0.61)		
V4	6.77 (± 0.47)	6.77 (± 0.47)		

## Statistical analyses

Statistical analysis title	Changes in QOLRAD domain score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[29]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.17
upper limit	0.54
Variability estimate	Standard deviation
Dispersion value	0.65

Notes:

[29] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Changes in QOLRAD domain score (V2 vs. V4)
----------------------------	--

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[30]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.57
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	0.78
Variability estimate	Standard deviation
Dispersion value	0.74

Notes:

[30] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: QOLRAD domain "vitality"

End point title	QOLRAD domain "vitality"
End point description:	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	5.48 (± 1.14)	5.48 (± 1.14)		
V3	5.94 (± 0.93)	5.94 (± 0.93)		
V4	6.37 (± 0.79)	6.37 (± 0.79)		

### Statistical analyses

Statistical analysis title	Changes in QOLRAD domain score (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[31]</sup>
P-value	= 0.003
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.15
upper limit	0.75
Variability estimate	Standard deviation
Dispersion value	1.08

Notes:

[31] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Changes in QOLRAD domain score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[32]</sup>
P-value	< 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	1.17
Variability estimate	Standard deviation
Dispersion value	1

Notes:

[32] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: SF-12 questionnaire - Question 1

End point title	SF-12 questionnaire - Question 1
End point description:	
Question 1: General health condition	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	2.49 (± 0.72)	2.49 (± 0.72)		
V3	2.42 (± 0.66)	2.42 (± 0.66)		
V4	2.38 (± 0.79)	2.38 (± 0.79)		

## Statistical analyses

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[33]</sup>
P-value	= 0.438
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.27
upper limit	0.12
Variability estimate	Standard deviation
Dispersion value	0.7

Notes:

[33] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[34]</sup>
P-value	= 0.254
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.37
upper limit	0.1
Variability estimate	Standard deviation
Dispersion value	0.83

Notes:

[34] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: SF-12 questionnaire - Question 2

End point title	SF-12 questionnaire - Question 2
-----------------	----------------------------------

End point description:

Question 2: Difficulties with moderate physical activities

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	2.85 (± 0.36)	2.85 (± 0.36)		
V3	2.89 (± 0.32)	2.89 (± 0.32)		
V4	2.94 (± 0.23)	2.94 (± 0.23)		

## Statistical analyses

Statistical analysis title	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[35]</sup>
P-value	= 0.485
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.07
upper limit	0.15
Variability estimate	Standard deviation
Dispersion value	0.39

Notes:

[35] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Change in SF-12 score (V2 vs. V4)
----------------------------	-----------------------------------

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[36]</sup>
P-value	= 0.058
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0.2
Variability estimate	Standard deviation
Dispersion value	0.35

Notes:

[36] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: SF-12 questionnaire - Question 3

End point title	SF-12 questionnaire - Question 3
End point description:	
Question 3: Difficulties climbing stairs	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	2.87 (± 0.34)	2.87 (± 0.34)		
V3	2.89 (± 0.32)	2.89 (± 0.32)		
V4	2.94 (± 0.23)	2.94 (± 0.23)		

### Statistical analyses

Statistical analysis title	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[37]</sup>
P-value	= 0.659
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.07
upper limit	0.11
Variability estimate	Standard deviation
Dispersion value	0.31

Notes:

[37] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[38]</sup>
P-value	= 0.044
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0.15
Variability estimate	Standard deviation
Dispersion value	0.27

Notes:

[38] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

#### Secondary: SF-12 questionnaire - Question 4

End point title	SF-12 questionnaire - Question 4
End point description:	
Question 4: Less task completed than intended (physical health)	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	



End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	1.79 (± 0.41)	1.79 (± 0.41)		
V3	1.87 (± 0.34)	1.87 (± 0.34)		
V4	1.87 (± 0.34)	1.87 (± 0.34)		

## Statistical analyses

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[39]</sup>
P-value	= 0.209
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.21
Variability estimate	Standard deviation
Dispersion value	0.43

Notes:

[39] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[40]</sup>
P-value	= 0.252
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.21
Variability estimate	Standard deviation
Dispersion value	0.43

Notes:

[40] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: SF-12 questionnaire - Question 5

End point title	SF-12 questionnaire - Question 5
-----------------	----------------------------------

End point description:

Question 5 : Ability to only do certain things (physical health)

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	1.91 (± 0.30)	1.91 (± 0.30)		
V3	1.91 (± 0.30)	1.91 (± 0.30)		
V4	1.94 (± 0.23)	1.94 (± 0.23)		

## Statistical analyses

Statistical analysis title	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[41]</sup>
P-value	= 1
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.08
upper limit	0.08
Variability estimate	Standard deviation
Dispersion value	0.28

Notes:

[41] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Change in SF-12 score (V2 vs. V4)
----------------------------	-----------------------------------

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[42]</sup>
P-value	= 0.485
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.07
upper limit	0.15
Variability estimate	Standard deviation
Dispersion value	0.39

Notes:

[42] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: SF-12 questionnaire - Question 6

End point title	SF-12 questionnaire - Question 6
End point description:	
Question 4: Less task completed than intended (mental health)	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	1.68 (± 0.47)	1.68 (± 0.47)		
V3	1.79 (± 0.41)	1.79 (± 0.41)		
V4	1.87 (± 0.34)	1.87 (± 0.34)		

### Statistical analyses

Statistical analysis title	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[43]</sup>
P-value	= 0.033
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.009
upper limit	0.22
Variability estimate	Standard deviation
Dispersion value	0.38

Notes:

[43] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[44]</sup>
P-value	= 0.006
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	0.22
Variability estimate	Standard deviation
Dispersion value	0.44

Notes:

[44] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: SF-12 questionnaire - Question 7

End point title	SF-12 questionnaire - Question 7
End point description:	
Question 7 : Not being able to work concentrated (mental health)	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	1.89 (± 0.32)	1.89 (± 0.32)		
V3	1.87 (± 0.34)	1.87 (± 0.34)		
V4	1.94 (± 0.23)	1.94 (± 0.23)		

## Statistical analyses

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[45]</sup>
P-value	= 0.659
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.11
upper limit	0.07
Variability estimate	Standard deviation
Dispersion value	0.31

Notes:

[45] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[46]</sup>
P-value	= 0.083
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.01
upper limit	0.13
Variability estimate	Standard deviation
Dispersion value	0.23

Notes:

[46] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: SF-12 questionnaire - Question 8

End point title	SF-12 questionnaire - Question 8
-----------------	----------------------------------

End point description:

Question 8: Pain during daily routine

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	1.66 (± 0.73)	1.66 (± 0.73)		
V3	1.40 (± 0.72)	1.40 (± 0.72)		
V4	1.17 (± 0.38)	1.17 (± 0.38)		

## Statistical analyses

Statistical analysis title	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[47]</sup>
P-value	= 0.056
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.54
upper limit	0.01
Variability estimate	Standard deviation
Dispersion value	0.98

Notes:

[47] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Change in SF-12 score (V2 vs. V4)
----------------------------	-----------------------------------

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[48]</sup>
P-value	= 0.001
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.72
upper limit	-0.27
Variability estimate	Standard deviation
Dispersion value	0.8

Notes:

[48] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: SF-12 questionnaire - Question 9

End point title	SF-12 questionnaire - Question 9
End point description:	
Question 9: calm and relaxed	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	2.92 (± 1.04)	2.92 (± 1.04)		
V3	2.68 (± 1.00)	2.68 (± 1.00)		
V4	2.60 (± 1.17)	2.60 (± 1.17)		

### Statistical analyses

Statistical analysis title	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[49]</sup>
P-value	= 0.14
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.58
upper limit	0.09
Variability estimate	Standard deviation
Dispersion value	1.19

Notes:

[49] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[50]</sup>
P-value	= 0.107
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.72
upper limit	0.08
Variability estimate	Standard deviation
Dispersion value	1.42

Notes:

[50] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: SF-12 questionnaire - Question 10

End point title	SF-12 questionnaire - Question 10
End point description:	
Question 10: Full of energy	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	



End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	3.23 ( $\pm$ 1.14)	3.23 ( $\pm$ 1.14)		
V3	3.08 ( $\pm$ 1.12)	3.08 ( $\pm$ 1.12)		
V4	2.68 ( $\pm$ 0.98)	2.68 ( $\pm$ 0.98)		

## Statistical analyses

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[51]</sup>
P-value	= 0.28
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	0.13
Variability estimate	Standard deviation
Dispersion value	1.01

Notes:

[51] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[52]</sup>
P-value	= 0.002
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.9
upper limit	-0.2
Variability estimate	Standard deviation
Dispersion value	1.25

Notes:

[52] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: SF-12 questionnaire - Question 11

End point title	SF-12 questionnaire - Question 11
-----------------	-----------------------------------

End point description:

Question 11: discouraged and sad

End point type	Secondary
----------------	-----------

End point timeframe:

V2 (baseline)

V3 (after 3 weeks)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	52	52		
Units: score				
arithmetic mean (standard deviation)				
V2	4.90 (± 0.87)	4.90 (± 0.87)		
V3	5.02 (± 0.94)	5.02 (± 0.94)		
V4	4.98 (± 1.08)	4.98 (± 1.08)		

## Statistical analyses

Statistical analysis title	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other <sup>[53]</sup>
P-value	= 0.371
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.38
Variability estimate	Standard deviation
Dispersion value	0.92

Notes:

[53] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

Statistical analysis title	Change in SF-12 score (V2 vs. V4)
----------------------------	-----------------------------------

Comparison groups	Treatment v FAS population
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other <sup>[54]</sup>
P-value	= 0.584
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.21
upper limit	0.36
Variability estimate	Standard deviation
Dispersion value	1.01

Notes:

[54] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: SF-12 questionnaire - Question 12

End point title	SF-12 questionnaire - Question 12
End point description:	
Question 12: Impairment of contact with other people	
End point type	Secondary
End point timeframe:	
V2 (baseline)	
V3 (after 3 weeks)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: score				
arithmetic mean (standard deviation)				
V2	4.51 (± 0.72)	4.51 (± 0.72)		
V3	4.53 (± 0.82)	4.53 (± 0.82)		
V4	4.55 (± 0.77)	4.55 (± 0.77)		

### Statistical analyses

Statistical analysis title	Change in SF-12 score (V2 vs. V3)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[55]</sup>
P-value	= 0.855
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.19
upper limit	0.23
Variability estimate	Standard deviation
Dispersion value	0.75

Notes:

[55] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

<b>Statistical analysis title</b>	Change in SF-12 score (V2 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[56]</sup>
P-value	= 0.749
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.28
Variability estimate	Standard deviation
Dispersion value	0.85

Notes:

[56] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: ALAT (Alanine Transaminase)

End point title	ALAT (Alanine Transaminase)
End point description:	
End point type	Secondary
End point timeframe:	
V1 (screening)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: µkat/l				
arithmetic mean (standard deviation)				
V1	0.430 (± 0.184)	0.430 (± 0.184)		
V4	0.408 (± 0.181)	0.408 (± 0.181)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of ALAT (V1 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[57]</sup>
P-value	= 0.152
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.022
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.01
Variability estimate	Standard deviation
Dispersion value	0.111

Notes:

[57] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: ASAT (Aspartate transaminase)

End point title	ASAT (Aspartate transaminase)
End point description:	
End point type	Secondary
End point timeframe:	
V1 (screening)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: µkat/l				
arithmetic mean (standard deviation)				
V1	0.402 (± 0.115)	0.402 (± 0.115)		
V4	0.400 (± 0.124)	0.400 (± 0.124)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of ASAT (V1 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[58]</sup>
P-value	= 0.893
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.002
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.03
upper limit	0.03
Variability estimate	Standard deviation
Dispersion value	0.091

Notes:

[58] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: AP (Alkaline phosphatase)

End point title	AP (Alkaline phosphatase)
End point description:	
End point type	Secondary
End point timeframe:	
V1 (screening)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: $\mu\text{kat/l}$				
arithmetic mean (standard deviation)				
V1	1.07 ( $\pm$ 0.28)	1.07 ( $\pm$ 0.28)		
V4	1.10 ( $\pm$ 0.28)	1.10 ( $\pm$ 0.28)		

## Statistical analyses

Statistical analysis title	Change of AP (V1 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[59]</sup>
P-value	= 0.221
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.02
upper limit	0.07
Variability estimate	Standard deviation
Dispersion value	0.15

Notes:

[59] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: g-GT (Gamma-glutamyltransferase)

End point title	g-GT (Gamma-glutamyltransferase)
End point description:	
End point type	Secondary
End point timeframe:	
V1 (screening)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: $\mu\text{kat/l}$				
arithmetic mean (standard deviation)				
V1	0.374 ( $\pm$ 0.225)	0.374 ( $\pm$ 0.225)		

V4	0.362 ( $\pm$ 0.218)	0.362 ( $\pm$ 0.218)		
----	----------------------	----------------------	--	--

## Statistical analyses

<b>Statistical analysis title</b>	Change of g-GT (V1 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[60]</sup>
P-value	= 0.354
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.012
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.04
upper limit	0.02
Variability estimate	Standard deviation
Dispersion value	0.091

Notes:

[60] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: Bilirubin

End point title	Bilirubin
End point description:	
End point type	Secondary
End point timeframe:	
V1 (screening)	
V4 (after 6 weeks)	

<b>End point values</b>	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: $\mu$ mol/l				
arithmetic mean (standard deviation)				
V1	13.59 ( $\pm$ 7.74)	13.59 ( $\pm$ 7.74)		
V4	13.84 ( $\pm$ 8.60)	13.84 ( $\pm$ 8.60)		



## Statistical analyses

<b>Statistical analysis title</b>	Change of bilirubin (V1 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[61]</sup>
P-value	= 0.789
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.65
upper limit	2.16
Variability estimate	Standard deviation
Dispersion value	6.91

Notes:

[61] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: Triglycerides

End point title	Triglycerides
-----------------	---------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V1 (screening)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: mmol/l				
arithmetic mean (standard deviation)				
V1	1.26 (± 0.66)	1.26 (± 0.66)		
V4	1.20 (± 0.64)	1.20 (± 0.64)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of triglycerides (V1 vs. V4)
Comparison groups	Treatment v FAS population

Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[62]</sup>
P-value	= 0.465
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	-0.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.22
upper limit	0.11
Variability estimate	Standard deviation
Dispersion value	0.58

Notes:

[62] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

## Secondary: Cholesterol

End point title	Cholesterol
End point description:	
End point type	Secondary
End point timeframe:	
V1 (screening)	
V4 (after 6 weeks)	

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: mmol/l				
arithmetic mean (standard deviation)				
V1	5.19 (± 1.05)	5.19 (± 1.05)		
V4	5.27 (± 1.10)	5.27 (± 1.10)		

## Statistical analyses

<b>Statistical analysis title</b>	Change of cholesterol (V1 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[63]</sup>
P-value	= 0.274
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.08

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.07
upper limit	0.23
Variability estimate	Standard deviation
Dispersion value	0.54

Notes:

[63] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: LDL (Low-density lipoprotein)

End point title	LDL (Low-density lipoprotein)
-----------------	-------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V1 (screening)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: mmol/l				
arithmetic mean (standard deviation)				
V1	3.23 (± 0.94)	3.23 (± 0.94)		
V4	3.23 (± 0.97)	3.23 (± 0.97)		

### Statistical analyses

Statistical analysis title	Change of LDL (V1 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[64]</sup>
P-value	= 0.909
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.13
upper limit	0.14
Variability estimate	Standard deviation
Dispersion value	0.47

Notes:

[64] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: HDL (High-density lipoprotein)

End point title	HDL (High-density lipoprotein)
-----------------	--------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V1 (screening)

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: mmol/l				
arithmetic mean (standard deviation)				
V1	1.45 (± 0.36)	1.45 (± 0.36)		
V4	1.48 (± 0.34)	1.48 (± 0.34)		

### Statistical analyses

Statistical analysis title	Change of HDL (V1 vs. V4)
Comparison groups	Treatment v FAS population
Number of subjects included in analysis	106
Analysis specification	Pre-specified
Analysis type	other <sup>[65]</sup>
P-value	= 0.259
Method	Wilcoxon signed-rank test
Parameter estimate	Mean difference (final values)
Point estimate	0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.02
upper limit	0.08
Variability estimate	Standard deviation
Dispersion value	0.16

Notes:

[65] - explorative

Treatment arm was added due to work around for single arm trial. Thus, a total of 106 instead of 53 are given automatically by the system.

### Secondary: Global Assessment of Efficacy by Investigator

End point title	Global Assessment of Efficacy by Investigator
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: percent				
number (not applicable)				
very good	39.6	39.6		
good	54.7	54.7		
moderate	5.7	5.7		
bad	0.0	0.0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Global Assessment of Efficacy by Patients

End point title	Global Assessment of Efficacy by Patients
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: percent				
number (not applicable)				
very good	37.7	37.7		
good	54.7	54.7		
moderate	5.7	5.7		
bad	1.9	1.9		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Global Assessment of Tolerability by Investigator

End point title Global Assessment of Tolerability by Investigator

End point description:

End point type Secondary

End point timeframe:

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: percentage				
number (not applicable)				
very good	83.0	83.0		
good	17.0	17.0		
moderate	0.0	0.0		
bad	0.0	0.0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Global Assessment of Tolerability by Patients

End point title Global Assessment of Tolerability by Patients

End point description:

End point type Secondary

End point timeframe:

V4 (after 6 weeks)

End point values	Treatment	FAS population		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	53	53		
Units: percent				
number (not applicable)				
very good	79.2	79.2		
good	18.9	18.9		
moderate	1.9	1.9		
bad	0.0	0.0		

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

V3 - V4

Adverse event reporting additional description:

Recording and Dokumentation of AEs at V3 (after 3 weeks) and V4 (after 6 weeks)

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.0
--------------------	------

### Reporting groups

Reporting group title	Safety-Population
-----------------------	-------------------

Reporting group description: -

Serious adverse events	Safety-Population		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 56 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Safety-Population		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 56 (7.14%)		
Injury, poisoning and procedural complications			
Contusion	Additional description: Contusion, right hand		
subjects affected / exposed	1 / 56 (1.79%)		
occurrences (all)	1		
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 56 (1.79%)		
occurrences (all)	1		
Gastrointestinal disorders			
Meteorism			



subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 1		
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 November 2013	<ul style="list-style-type: none"><li>- Adjustment of the age for inclusion criterions: 18-65 years instead of 18-55 years</li><li>- Adjustment of exclusion criterions: Helicobacter pylori infection deleted as exclusion criterion</li><li>- New chapter (10.7): Detection of a possible helicobacter pylori infection with a 13C-urea breath test at visit 1</li><li>-Amendment to the chapter 13.4 "statistical methods": Formation of subgroups to examine potential influencing factors on the course of therapy now possible</li></ul>
17 December 2013	<ul style="list-style-type: none"><li>- Amendment to Chapter 10.7 regarding the possibility of helicobacter pylori infection: Exclusion of the patient from the study if investigator decides that an antibiotic therapy is required du to H. pylori infection.</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported